Compare Eli Lilly And Co (LLY) vs Invesco S&P 500 Low Volatility ETF (SPLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Invesco S&P 500 Low Volatility ETF — how do they compare? Eli Lilly And Co trades at $1,177.75 (market cap $1.04T), while Invesco S&P 500 Low Volatility ETF trades at $72.16 (market cap $6.94B). The key difference: Eli Lilly And Co is far larger — about 149.9× Invesco S&P 500 Low Volatility ETF's market cap, and Eli Lilly And Co pays a 0.59% dividend while Invesco S&P 500 Low Volatility ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Invesco S&P 500 Low Volatility ETF for 123 Days on average.
| LLY | SPLV | |
|---|---|---|
Market Cap | $1.04T | $6.94B |
Volume | 3,064,878 | 1,663,703 |
Sector | Health | — |
52-Week High | $1.28K | $77.97 |
52-Week Low | $799.57 | $70.30 |
Typical Hold Time | 93 Days | 123 Days |
Enterprise Value | $1.09T | — |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.
SPLV, the Invesco S&P 500 Low Volatility ETF, trades at $72.14 with a 1.29% daily gain, though technical indicators show a bearish trend with moving averages signaling caution. The ETF's sector allocation to Utilities, Real Estate, and Financials has contributed to underperformance relative to the broader S&P 500, with a 5% return versus 17% for the index. Recent dividend distributions of $0.14 per share provide income support amid market volatility.
The outlook remains neutral with valuation concerns at a 19.5x P/E ratio creating headwinds, while geopolitical tensions and sector-specific risks pose challenges. Opportunities exist for investors seeking stability during market uncertainty, though growth potential appears limited compared to broader market ETFs. Key risks include continued sector underperformance and macroeconomic pressures on defensive holdings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Invesco S&P 500 Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the "index Provider") compiles, maintains and calculates the underlying index, which is designed to measure the performance of the 100 least volatile constituents of the S&P 500 ® Index over the past 12 months as determined by the index Provider.
Read more on SPLV →
